Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
20vPnC vs 13vPnC in Chinese adults 50+
NCT07019909Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jul 2025
- Primary completion
- Jan 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Prevnar 20 in pneumococcal disease (2 arms), sponsored by Pfizer. Primary endpoints: Percentage of participants reporting prompted local reactions within 7 days following vaccination, Percentage of participants reporting prompted systemic events within 7 days following vaccination and 3 more. Started Jul 2025; status: completed.
02
Drugs
Prevnar 20
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT07019909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07019909.